Stock Expert AI
VSMD company logo

Vasamed, Inc. (VSMD) — AI Stock Analysis

Vasamed, Inc. focuses on designing, manufacturing, and distributing products for hemodynamic health assessment. Their SensiLase PAD-IQ system and related software serve clinicians and patients in the United States.

Company Overview

TL;DR:

Vasamed, Inc. focuses on designing, manufacturing, and distributing products for hemodynamic health assessment. Their SensiLase PAD-IQ system and related software serve clinicians and patients in the United States.
Vasamed Incorporated, established in 1988, specializes in hemodynamic health assessment solutions, including the SensiLase PAD-IQ system. Serving clinicians and patients in the United States, the company provides diagnostic tools and software for managing peripheral artery disease and wound care, operating within the medical instruments and supplies sector.

About VSMD

Founded in 1988 and headquartered in Eden Prairie, Minnesota, Vasamed Incorporated operates within the healthcare sector, specifically focusing on medical instruments and supplies. The company designs, licenses, manufactures, and distributes products, software, and services aimed at assessing and managing hemodynamic health. Vasamed's flagship product is the SensiLase PAD-IQ system, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation using Doppler-obtained pressures. This system aids in the diagnosis and management of peripheral artery disease (PAD). In addition to PAD-IQ, Vasamed offers Wound Imaging & SmartDraw wound measurement systems, providing tools for clinicians to assess and track wound healing progress. The company also provides PAD-IQ Studycast, a service that facilitates rapid transmission of diagnostic tests to vascular specialists for interpretation and medically indicated therapeutic intervention. Vasamed serves clinicians and patients in the United States, offering a custom carrying case to secure and protect the PAD-IQ system, ensuring its portability and durability in clinical settings. Vasamed's solutions are designed to improve the accuracy and efficiency of hemodynamic assessments, supporting better patient outcomes in vascular health management.

Investment Thesis

Vasamed, Inc. operates in the niche market of hemodynamic health assessment, primarily through its SensiLase PAD-IQ system. While the company's solutions cater to a specific need in vascular health management, the negative profit margin of -352.6% and gross margin of -5.0% raise concerns about its financial sustainability. Growth catalysts include potential expansion of the PAD-IQ system's applications and increased adoption of PAD-IQ Studycast for remote diagnostics. However, the company's reliance on a limited product line and the competitive landscape of medical instruments and supplies pose risks. Investors should closely monitor Vasamed's ability to improve its financial performance and capitalize on growth opportunities within the hemodynamic health market.

Industry Context

Vasamed Incorporated operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. This industry is characterized by technological advancements, stringent regulatory requirements, and a competitive landscape featuring both large multinational corporations and smaller niche players. Market trends include a growing demand for non-invasive diagnostic tools, driven by an aging population and increasing prevalence of chronic diseases such as peripheral artery disease (PAD). Vasamed's focus on hemodynamic health assessment positions it within this growing market, but it faces competition from companies offering similar diagnostic solutions. The industry is also subject to regulatory oversight by agencies such as the FDA, which impacts product development and market access.
Medical - Instruments & Supplies
Healthcare

Growth Opportunities

  • Expansion of PAD-IQ System Applications: Vasamed can explore expanding the applications of its PAD-IQ system beyond PAD diagnosis to include other vascular conditions. This could involve developing new software modules or hardware attachments that enable the system to assess different hemodynamic parameters or target specific patient populations. The market for vascular diagnostic tools is estimated to reach $10 billion by 2028, providing a significant opportunity for Vasamed to increase its market share by diversifying the applications of its flagship product. Timeline: 2-3 years.
  • Increased Adoption of PAD-IQ Studycast: Vasamed can focus on increasing the adoption of its PAD-IQ Studycast service, which facilitates remote transmission of diagnostic tests to vascular specialists. This service addresses the growing demand for telemedicine solutions and can improve access to specialized care, particularly in rural or underserved areas. The telemedicine market is projected to reach $400 billion by 2027, presenting a substantial opportunity for Vasamed to expand its Studycast service and generate recurring revenue. Timeline: 1-2 years.
  • Strategic Partnerships with Healthcare Providers: Vasamed can pursue strategic partnerships with hospitals, clinics, and vascular centers to integrate its products and services into their existing workflows. This could involve offering bundled solutions that combine the PAD-IQ system with training, support, and data analytics services. By partnering with established healthcare providers, Vasamed can gain access to a broader customer base and increase its market penetration. Timeline: Ongoing.
  • Development of New Wound Care Solutions: Vasamed can leverage its expertise in hemodynamic assessment to develop new wound care solutions that complement its existing Wound Imaging & SmartDraw system. This could involve incorporating advanced imaging technologies or developing novel wound dressings that promote healing and reduce the risk of infection. The wound care market is expected to reach $22 billion by 2029, providing a significant opportunity for Vasamed to expand its product portfolio and address unmet needs in wound management. Timeline: 3-5 years.
  • Geographic Expansion Beyond the United States: Vasamed can explore expanding its operations beyond the United States to target international markets with a high prevalence of vascular disease. This could involve adapting its products and services to meet the specific needs of different healthcare systems and regulatory environments. By expanding its geographic reach, Vasamed can diversify its revenue streams and reduce its reliance on the U.S. market. Timeline: 4-6 years.
  • Vasamed Incorporated specializes in hemodynamic health assessment products and services.
  • The company's flagship product is the SensiLase PAD-IQ system, used for diagnosing peripheral artery disease (PAD).
  • Vasamed offers PAD-IQ Studycast, a service for rapid transmission of diagnostic tests to vascular specialists.
  • The company's profit margin is -352.6%, indicating significant losses.
  • Vasamed operates in the medical instruments and supplies industry, serving clinicians and patients in the United States.

What They Do

  • Designs, licenses, manufactures, and distributes products for hemodynamic health assessment.
  • Offers the SensiLase PAD-IQ system for skin perfusion pressure, pulse volume recording, and ankle brachial index calculation.
  • Provides Wound Imaging & SmartDraw wound measurement systems.
  • Offers PAD-IQ Studycast for rapid transmission of diagnostic tests to vascular specialists.
  • Provides custom carrying cases to secure and protect the PAD-IQ system.
  • Serves clinicians and patients in the United States.

Business Model

  • Sales of SensiLase PAD-IQ system and related accessories.
  • Licensing of software for hemodynamic assessment.
  • Service revenue from PAD-IQ Studycast for remote diagnostics.
  • Distribution of Wound Imaging & SmartDraw wound measurement systems.
  • Clinicians specializing in vascular health.
  • Hospitals and clinics offering vascular diagnostic services.
  • Vascular specialists interpreting diagnostic tests.
  • Patients requiring hemodynamic health assessment and management.
  • Specialized Product Portfolio: Vasamed's focus on hemodynamic health assessment provides a niche market position.
  • Proprietary Technology: The SensiLase PAD-IQ system incorporates proprietary technology for accurate hemodynamic measurements.
  • Established Customer Relationships: Vasamed has established relationships with clinicians and healthcare providers in the United States.
  • PAD-IQ Studycast: Vasamed offers PAD-IQ Studycast for rapid transmission of diagnostic tests to vascular specialists.

Catalysts

  • Upcoming: Potential expansion of PAD-IQ system applications to other vascular conditions (timeline: 2-3 years).
  • Ongoing: Increased adoption of PAD-IQ Studycast for telemedicine (timeline: 1-2 years).
  • Ongoing: Strategic partnerships with healthcare providers.
  • Upcoming: Development of new wound care solutions (timeline: 3-5 years).
  • Upcoming: Geographic expansion beyond the United States (timeline: 4-6 years).

Risks

  • Ongoing: Negative profit margin of -352.6% indicates financial instability.
  • Ongoing: Gross margin of -5.0% suggests challenges in cost management.
  • Potential: Competition from larger medical device companies.
  • Potential: Regulatory changes impacting product development and market access.
  • Potential: Economic downturn affecting healthcare spending.

Strengths

  • Specialized product portfolio focused on hemodynamic health assessment.
  • Proprietary SensiLase PAD-IQ system for accurate measurements.
  • PAD-IQ Studycast service for remote diagnostics.
  • Established relationships with clinicians and healthcare providers.

Weaknesses

  • Negative profit margin of -352.6% indicates financial instability.
  • Gross margin of -5.0% suggests challenges in cost management.
  • Limited product line focused primarily on PAD diagnosis.
  • Reliance on the U.S. market.

Opportunities

  • Expansion of PAD-IQ system applications to other vascular conditions.
  • Increased adoption of PAD-IQ Studycast for telemedicine.
  • Strategic partnerships with healthcare providers.
  • Development of new wound care solutions.

Threats

  • Competition from larger medical device companies.
  • Regulatory changes impacting product development and market access.
  • Economic downturn affecting healthcare spending.
  • Technological advancements rendering existing products obsolete.

Competitors & Peers

  • Avinger, Inc. — Focuses on developing and commercializing image-guided, catheter-based systems for treating peripheral artery disease. — (ABMT)
  • Asensus Surgical, Inc. — Develops and commercializes surgical robotic systems. — (ASFX)
  • Azafran Corp. — Unknown differentiation. — (AZFL)
  • China Nuokang Bio-Pharm. Inc. — Focuses on manufacturing, marketing, and distributing pharmaceutical products. — (CNNC)
  • ECGI Holding, Inc. — Unknown differentiation. — (ECGI)

Key Metrics

  • Volume: 0
  • MoonshotScore: 59/100

Company Profile

  • CEO: Paulita LaPlante
  • Headquarters: Eden Prairie, US
  • Founded: 1996

AI Insight

AI analysis pending for VSMD
  • OTC Tier: OTC Other
  • Disclosure Status: Unknown

常见问题

What does Vasamed, Inc. do?

Vasamed, Inc. specializes in the design, manufacture, and distribution of medical devices and software for hemodynamic health assessment. Its primary product, the SensiLase PAD-IQ system, is used by clinicians to diagnose and manage peripheral artery disease (PAD) through non-invasive measurements like skin perfusion pressure and ankle brachial index. The company also offers PAD-IQ Studycast, a service facilitating rapid transmission of diagnostic tests to vascular specialists. Vasamed serves clinicians and patients in the United States, providing tools to improve vascular health management.

What do analysts say about VSMD stock?

Due to the limited information available and the OTC Other listing, a comprehensive analyst consensus on VSMD stock is unavailable. Key valuation metrics such as P/E ratio (-0.00) and negative profit margin (-352.6%) suggest the company is not currently profitable. Growth considerations would focus on the company's ability to expand the applications of its PAD-IQ system, increase adoption of PAD-IQ Studycast, and manage its financial performance. Investors should conduct thorough due diligence and consider the risks associated with OTC-listed stocks.

What are the main risks for VSMD?

The main risks for Vasamed, Inc. include its negative profit margin and gross margin, indicating financial instability and challenges in cost management. Competition from larger medical device companies poses a threat to its market share. As an OTC-listed company, VSMD faces risks associated with limited financial disclosure, low liquidity, and potential regulatory scrutiny. Additionally, changes in healthcare regulations and economic downturns could impact the company's business and financial performance. Investors should carefully consider these risks before investing in VSMD.

Is VSMD a good investment right now?

Use the AI score and analyst targets on this page to evaluate Vasamed, Inc. (VSMD). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for VSMD?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Vasamed, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find VSMD financial statements?

Vasamed, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about VSMD?

Analyst consensus targets and ratings for Vasamed, Inc. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is VSMD stock?

Check the beta and historical price range on this page to assess Vasamed, Inc.'s volatility relative to the broader market.